









Markets
/
Stocks
/
nasdaq-ctxr
/

Citius Pharmaceuticals Inc

CTXR

0.755USD

+0.043+6.00%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

13.64MMarket Cap

LossP/E TTM



Citius Pharmaceuticals Inc

0.755

+0.043+6.00%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Citius Pharmaceuticals Inc

Currency: USD Updated: 2026-02-06

Key Insights

Citius Pharmaceuticals Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 207 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Citius Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

207 / 392

Overall Ranking

406 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Citius Pharmaceuticals Inc Highlights

StrengthsRisks

Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.

Fairly Valued

The company’s latest PE is -0.22, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 2.08M shares, increasing 41.27% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 199.26K shares of this stock.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

5.000

Target Price

+548.17%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Citius Pharmaceuticals Inc is 6.06, ranking 294 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.06

Change



Financials

5.93

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.60

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Citius Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Citius Pharmaceuticals Inc is 7.02, ranking 186 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.22, which is -97.94% below the recent high of -0.00 and -3390.23% above the recent low of -7.79.

Score

Industry at a Glance

Previous score

7.02

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 207/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Citius Pharmaceuticals Inc is 7.00, ranking 311 out of 392 in the Biotechnology & Medical Research industry. The average price target is 5.00, with a high of 6.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

5.000

Target Price

+548.17%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Citius Pharmaceuticals Inc

CTXR

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Citius Pharmaceuticals Inc is 2.87, ranking 371 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.87 and the support level at 0.67, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

2.82

Change

0.05

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.004

Neutral

RSI(14)

39.598

Neutral

STOCH(KDJ)(9,3,3)

26.866

Neutral

ATR(14)

0.060

Low Volatility

CCI(14)

-113.253

Sell

Williams %R

63.533

Sell

TRIX(12,20)

-0.905

Sell

StochRSI(14)

99.639

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.756

Sell

MA10

0.773

Sell

MA20

0.812

Sell

MA50

0.965

Sell

MA100

1.138

Sell

MA200

1.159

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Citius Pharmaceuticals Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 8.77%, representing a quarter-over-quarter decrease of 5.52%. The largest institutional shareholder is The Vanguard, holding a total of 199.26K shares, representing 0.96% of shares outstanding, with 67.37% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Heights Capital Management, Inc.

1.46M

Mazur (Leonard L)

410.21K

The Vanguard Group, Inc.

Star Investors

166.39K

+107.72%

Geode Capital Management, L.L.C.

119.77K

+57.40%

Holubiak (Myron Z)

79.69K

UBS Financial Services, Inc.

25.56K

-86.73%

BlackRock Institutional Trust Company, N.A.

69.85K

Susquehanna International Group, LLP

48.19K

+239.36%

Northern Trust Investments, Inc.

27.02K

+111.58%

GWM Advisors LLC

25.40K

+1.60%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Citius Pharmaceuticals Inc. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is 1.52. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.